SUBSCRIBE
SUBSCRIBE

Chroma Medicine, Inc.

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio.

NEWS
Catherine Stehman-Breen, CEO, Chroma Medicine/comp
Drug Development
Chroma Scores $135M for Epigenetic Editing Approach
Backed by Google Ventures, ARCH Venture Partners and more, Chroma Medicine announced the closing of a $135 million Series B financing Wednesday.
March 1, 2023
 · 
2 min read
 · 
Kate Goodwin
Business
Top Life Sciences Startups to Watch in 2023
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
December 5, 2022
 · 
15 min read
 · 
BioSpace Editorial Staff
IN THE PRESS
Genetown
Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023
May 19, 2023
 · 
3 min read
Genetown
Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting
May 18, 2023
 · 
3 min read
Genetown
Chroma Medicine to Present First Data Demonstrating Promise of Its Epigenetic Editing Platform at 26th ASGCT Annual Meeting
May 2, 2023
 · 
3 min read
Genetown
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
March 1, 2023
 · 
3 min read
Load More
AWARDS
  • NextGen Class of 2023
JOBS